Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated
with Cabozantinib

J 2020

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

BÜCHLER, Tomáš, Marie KOPECKA, Anezka ZEMANKOVA, Marketa WIESNEROVA, Marketa STRECKOVA et. al.

Základní údaje

Originální název

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

Autoři

BÜCHLER, Tomáš (203 Česká republika, garant), Marie KOPECKA (203 Česká republika), Anezka ZEMANKOVA (203 Česká republika), Marketa WIESNEROVA (203 Česká republika), Marketa STRECKOVA (203 Česká republika), Aneta ROZSYPALOVA (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí) a Igor RICHTER (203 Česká republika)

Vydání

Targeted Oncology, Dordrecht, Springer, 2020, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.493

Kód RIV

RIV/00216224:14110/20:00116254

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11523-020-00744-8

UT WoS

000555352100001

Klíčová slova anglicky

Sarcopenia; Metastatic Renal Cell Carcinoma; Cabozantinib

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 10. 2020 13:33, Mgr. Tereza Miškechová

Anotace

V originále

Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra. Results The median muscle mass index at CT1 and CT2 was 52.2 cm(2)/m(2)(range 33.0-69.2 cm(2)/m(2)) and 49.1 cm(2)/m(2)(range 33.1-68.2 cm(2)/m(2)), respectively. Sarcopenia was initially present in 13 (44.8%) patients. The mean muscle mass change between CT1 and CT2 was - 2.2 cm(2)/m(2)(range - 10.1 to + 4.8cm(2)/m(2)). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-90) versus 79.8% (95% CI 62.1-90.6) in others (p= 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. Conclusions Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.

Citovat

BÜCHLER, Tomáš, Marie KOPECKA, Anezka ZEMANKOVA, Marketa WIESNEROVA, Marketa STRECKOVA, Aneta ROZSYPALOVA, Bohuslav MELICHAR, Alexandr POPRACH a Igor RICHTER. Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. Targeted Oncology. Dordrecht: Springer, 2020, roč. 15, č. 5, s. 673-679. ISSN 1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-020-00744-8.

@article{1674863,
   author = {Büchler, Tomáš and Kopecka, Marie and Zemankova, Anezka and Wiesnerova, Marketa and Streckova, Marketa and Rozsypalova, Aneta and Melichar, Bohuslav and Poprach, Alexandr and Richter, Igor},
   article_location = {Dordrecht},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s11523-020-00744-8},
   keywords = {Sarcopenia; Metastatic Renal Cell Carcinoma; Cabozantinib},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib},
   url = {https://link.springer.com/article/10.1007%2Fs11523-020-00744-8},
   volume = {15},
   year = {2020}
}

TY  - JOUR
ID  - 1674863
AU  - Büchler, Tomáš - Kopecka, Marie - Zemankova, Anezka - Wiesnerova, Marketa - Streckova, Marketa - Rozsypalova, Aneta - Melichar, Bohuslav - Poprach, Alexandr - Richter, Igor
PY  - 2020
TI  - Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
JF  - Targeted Oncology
VL  - 15
IS  - 5
SP  - 673-679
EP  - 673-679
PB  - Springer
SN  - 17762596
KW  - Sarcopenia
KW  - Metastatic Renal Cell Carcinoma
KW  - Cabozantinib
UR  - https://link.springer.com/article/10.1007%2Fs11523-020-00744-8
L2  - https://link.springer.com/article/10.1007%2Fs11523-020-00744-8
N2  - Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra. Results The median muscle mass index at CT1 and CT2 was 52.2 cm(2)/m(2)(range 33.0-69.2 cm(2)/m(2)) and 49.1 cm(2)/m(2)(range 33.1-68.2 cm(2)/m(2)), respectively. Sarcopenia was initially present in 13 (44.8%) patients. The mean muscle mass change between CT1 and CT2 was - 2.2 cm(2)/m(2)(range - 10.1 to + 4.8cm(2)/m(2)). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-90) versus 79.8% (95% CI 62.1-90.6) in others (p= 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. Conclusions Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.
ER  -

BÜCHLER, Tomáš, Marie KOPECKA, Anezka ZEMANKOVA, Marketa WIESNEROVA, Marketa STRECKOVA, Aneta ROZSYPALOVA, Bohuslav MELICHAR, Alexandr POPRACH a Igor RICHTER. Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. \textit{Targeted Oncology}. Dordrecht: Springer, 2020, roč.~15, č.~5, s.~673-679. ISSN~1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-020-00744-8.

Podrobný výpis o publikaci